Home Southeast Nashville, TN Insight Molecular Diagnostics COMPANY
5 open jobs · last seen Oct 23, 2026 · 4 sources
Keywords: diagnostics oncology precision medicine Kidney Transplant Kidney Transplant Rejection Cell-free DNA Non-Small-Cell Lung Carcinoma Adjuvant Show all 8 keywords
Location: Nashville, TN · source · Sep 21, 2026
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Director Product Market Development Remote, US Oct 15, 2026 Oct 16, 2026 Field Clinical Applications Specialist Remote, US Oct 15, 2026 Oct 16, 2026 Clinical Liaison and Market Dev. Leader Remote, US Oct 6, 2026 Oct 16, 2026 Molecular Technologist ll Franklin Lab, Franklin, TN, US Oct 3, 2026 Oct 16, 2026 Laboratory Operations & Manufacturing Manager Nashville Lab, Nashville, TN, US Aug 29, 2026 Oct 16, 2026
See all 5 jobs
At a glance HQ Nashville, TN source Region Southeast Latest trial —: GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial (2026-06) source Timeline 2026-06 Trial start —: GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial source ↗ Feb 11, 2026 Raise Follow-on offering — Registered direct: $26M (total, as published), announced Feb 11, 2026. Source: SEC filing. source ↗ Sep 8, 2025 Trial start —: Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring source ↗ Jan 28, 2022 Trial start —: Predictive Assay for Decision Making in Adjuvant Therapy source ↗ Upcoming milestones 2032-12 (ESTIMATED) · · GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial · NCT07551531 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $26.0M. Last 2 years.
Feb 11, 2026 Follow-on offering — Registered direct: $26M (total, as published), announced Feb 11, 2026. Source: SEC filing. source ↗ Clinical trials (lead sponsor) 3 Record Title Phase Status Start Primary completion NCT07551531 GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial Not listed Not yet recruiting 2026-06 2032-12 (estimated) NCT07060716 Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring Not listed Recruiting Sep 8, 2025 Nov 30, 2025 (estimated) NCT05032352 Predictive Assay for Decision Making in Adjuvant Therapy Not listed Terminated Jan 28, 2022 Oct 28, 2022 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
2025-02-24 Raise Private raise (SEC Form D): $21.7M sold; issuer “Oncocyte Corp”. Verified from the SEC filing. SEC filing ↗ Open jobs 5 Title Location (from posting, not HQ) Employer posted First seen Level Director Product Market Development Remote, US Oct 15, 2026 Oct 16, 2026 Senior Description Field Clinical Applications Specialist Remote, US Oct 15, 2026 Oct 16, 2026 Mid Description Clinical Liaison and Market Dev. Leader Remote, US Oct 6, 2026 Oct 16, 2026 Senior Description Molecular Technologist ll Franklin Lab, Franklin, TN, US Oct 3, 2026 Oct 16, 2026 Entry Description Laboratory Operations & Manufacturing Manager Nashville Lab, Nashville, TN, US Aug 29, 2026 Oct 16, 2026 Mid Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
